Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has entered into a securities purchase agreement for approximately $2.5 million, which will be used for marketing, general corporate purposes, and working capital [1][2]. Group 1: Offering Details - The company will issue a pre-funded warrant to purchase up to 625,156 shares of common stock at an effective purchase price of $4.00 per share, priced above the market under Nasdaq rules [2]. - The offering is expected to close on or about November 4, 2025, subject to customary closing conditions [2][3]. Group 2: Placement Agent and Registration - WestPark Capital, Inc. is acting as the exclusive placement agent for the offering [3]. - The securities have not been registered under the Securities Act of 1933 and are offered only to accredited investors. The company has agreed to file registration statements with the SEC for the resale of shares [4]. Group 3: Company Overview - Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on improving cancer therapy outcomes by developing novel drugs that sensitize cancer cells to radiation therapy [6]. - The company's mission is to advance precision medicine approaches to radiotherapy, enhancing treatment efficacy and patient quality of life [6].